Soleno Therapeutics (NASDAQ:SLNO) Sets New 12-Month Low Following Analyst Downgrade

Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares reached a new 52-week low on Thursday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The stock traded as low as $32.63 and last traded at $37.8340, with a volume of 898369 shares traded. The stock had previously closed at $41.01.

Other equities analysts have also recently issued research reports about the company. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research report on Monday, January 12th. Zacks Research cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Wells Fargo & Company decreased their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price (up from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $108.38.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

Institutional Trading of Soleno Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares during the period. Raymond James Financial Inc. acquired a new stake in Soleno Therapeutics during the 2nd quarter worth $25,000. Avanza Fonder AB raised its position in shares of Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after purchasing an additional 323 shares during the period. Principal Financial Group Inc. raised its holdings in Soleno Therapeutics by 11.9% during the 3rd quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after buying an additional 340 shares during the period. Finally, New York State Common Retirement Fund lifted its position in Soleno Therapeutics by 2.4% in the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after acquiring an additional 360 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Trading Up 2.6%

The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10. The business has a fifty day moving average price of $42.63 and a 200 day moving average price of $53.54. The company has a market capitalization of $2.02 billion, a P/E ratio of 169.88 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. On average, analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.